Publications

[1] K. Okoth et al., “Long term miscarriage-related hypertension and diabetes mellitus. Evidence from a United Kingdom population-based cohort study,” PLoS One, vol. 17, no. 1 January, Jan. 2022, doi: 10.1371/journal.pone.0261769.
[2] T. E. Gooden et al., “The risk of mental illness in people living with HIV in the UK: a propensity score-matched cohort study,” Lancet HIV, 2022, doi: 10.1016/S2352-3018(21)00319-2.
[3] K. Okoth, F. Crowe, T. Marshall, G. N. Thomas, K. Nirantharakumar, and N. J. Adderley, “Sex-specific temporal trends in the incidence and prevalence of cardiovascular disease in young adults: a population-based study using UK primary care data.,” Eur. J. Prev. Cardiol., Feb. 2022, doi: 10.1093/eurjpc/zwac024.
[4] K. M. Gokhale et al., “Metformin and risk of age-related macular degeneration in individuals with type 2 diabetes: a retrospective cohort study.,” Br. J. Ophthalmol., p. bjophthalmol-2021-319641, Feb. 2022, doi: 10.1136/bjophthalmol-2021-319641.
[5] N. J. Adderley et al., “Development and external validation of prognostic models for COVID-19 to support risk stratification in secondary care,” BMJ Open, vol. 12, no. 1, Jan. 2022, doi: 10.1136/bmjopen-2021-049506.
[6] M. Almulhem et al., “Ramadan is not associated with increased infection risk in Pakistani and Bangladeshi populations: Findings from controlled interrupted time series analysis of UK primary care data,” PLoS One, vol. 17, no. 1 January, Jan. 2022, doi: 10.1371/journal.pone.0262530.
[7] S. I. Lee et al., “Decreased renal function is associated with incident dementia: An IMRD-THIN retrospective cohort study in the UK.,” Alzheimers. Dement., Jan. 2022, doi: 10.1002/alz.12539.
[8] K. Gokhale et al., “The clinical profile and associated mortality in people with and without diabetes with Coronavirus disease 2019 on admission to acute hospital services,” Endocrinol. Diabetes Metab., vol. 5, no. 1, Jan. 2022, doi: 10.1002/edm2.309.
[9] J. S. Chandan et al., “Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID-19,” Arthritis Rheumatol., vol. 73, no. 5, pp. 731–739, May 2021, doi: 10.1002/ART.41593.
[10] C. Sainsbury et al., “Sodium-glucose co-transporter-2 inhibitors and susceptibility to COVID-19: A population-based retrospective cohort study,” Diabetes, Obes. Metab., vol. 23, no. 1, pp. 263–269, Jan. 2021, doi: 10.1111/DOM.14203.
[11] K. Phillips et al., “Trends in the pharmacological management of atrial fibrillation in UK general practice 2008-2018,” Heart, 2021, doi: 10.1136/HEARTJNL-2021-319338.
[12] R. Goel, J. S. Chandan, R. Thayakaran, N. J. Adderley, K. Nirantharakumar, and L. Harper, “Cardiovascular and Renal Morbidity in Takayasu Arteritis: A Population-Based Retrospective Cohort Study From the United Kingdom,” Arthritis Rheumatol., vol. 73, no. 3, pp. 504–511, Mar. 2021, doi: 10.1002/ART.41529.
[13] S. Haroon et al., “Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care,” BMC Infect. Dis., vol. 21, no. 1, Dec. 2021, doi: 10.1186/S12879-021-05951-W.
[14] W. Parry-Smith et al., “Postpartum haemorrhage and risk of mental ill health: A population-based longitudinal study using linked primary and secondary care databases,” J. Psychiatr. Res., vol. 137, pp. 419–425, May 2021, doi: 10.1016/J.JPSYCHIRES.2021.03.022.
[15] K. M. Gokhale, J. S. Chandan, K. Toulis, G. Gkoutos, P. Tino, and K. Nirantharakumar, “Data extraction for epidemiological research (DExtER): a novel tool for automated clinical epidemiology studies,” Eur. J. Epidemiol., vol. 36, no. 2, pp. 165–178, Feb. 2021, doi: 10.1007/S10654-020-00677-6.
[16] M. Almulhem et al., “Cardio-metabolic outcomes in South Asians compared to White Europeans in the United Kingdom: a matched controlled population-based cohort study,” BMC Cardiovasc. Disord., vol. 21, no. 1, Dec. 2021, doi: 10.1186/S12872-021-02133-Z.
[17] D. King et al., “Achalasia Is Associated With Atopy in Patients Younger Than 40 Years of Age,” Am. J. Gastroenterol., vol. 116, no. 2, pp. 416–419, Feb. 2021, doi: 10.14309/AJG.0000000000001006.
[18] H. M. Parretti, A. Subramanian, N. J. Adderley, S. Abbott, A. A. Tahrani, and K. Nirantharakumar, “Post-bariatric surgery nutritional follow-up in primary care: a population-based cohort study,” Br. J. Gen. Pract., vol. 71, no. 707, pp. E441–E449, Jun. 2021, doi: 10.3399/BJGP20X714161.
[19] P. Singh et al., “The Impact of Bariatric Surgery on Incident Microvascular Complications in Patients With Type 2 Diabetes: A Matched Controlled Population-Based Retrospective Cohort Study,” Diabetes Care, vol. 44, no. 1, pp. 116–124, Jan. 2021, doi: 10.2337/DC20-0571.
[20] J. S. Chandan et al., “Intimate Partner Violence and the Risk of Developing Fibromyalgia and Chronic Fatigue Syndrome,” J. Interpers. Violence, vol. 36, no. 21–22, pp. NP12279–NP12298, Nov. 2021, doi: 10.1177/0886260519888515.
[21] J. Wang et al., “Association of Metformin with Susceptibility to COVID-19 in People with Type 2 Diabetes,” J. Clin. Endocrinol. Metab., vol. 106, no. 5, pp. 1255–1268, May 2021, doi: 10.1210/CLINEM/DGAB067.
[22] A. Subramanian et al., “Increased COVID-19 infections in women with polycystic ovary syndrome: A population-based study,” Eur. J. Endocrinol., vol. 184, no. 5, pp. 637–645, May 2021, doi: 10.1530/EJE-20-1163.
[23] A. Subramanian, N. J. Adderley, G. V. Gkoutos, K. M. Gokhale, K. Nirantharakumar, and M. T. Krishna, “Ethnicity-based differences in the incident risk of allergic diseases and autoimmune disorders: A UK-based retrospective cohort study of 4.4 million participants,” Clin. Exp. Allergy, vol. 51, no. 1, pp. 144–147, Jan. 2021, doi: 10.1111/CEA.13741.
[24] J. Riley et al., “Social deprivation and incident diabetes-related foot disease in patients with type 2 diabetes: A population-based cohort study,” Diabetes Care, vol. 44, no. 3, pp. 731–739, 2021, doi: 10.2337/DC20-1027.
[25] D. King et al., “The Risk of Later Diagnosis of Inflammatory Bowel Disease in Patients with Dermatological Disorders Associated with Inflammatory Bowel Disease,” Inflamm. Bowel Dis., vol. 27, no. 11, pp. 1731–1739, Nov. 2021, doi: 10.1093/ibd/izaa344.
[26] D. T. Zemedikun et al., “Type 2 diabetes mellitus, glycaemic control, associated therapies and risk of rheumatoid arthritis: A retrospective cohort study,” Rheumatol. (United Kingdom), vol. 60, no. 12, pp. 5567–5575, Dec. 2021, doi: 10.1093/RHEUMATOLOGY/KEAB148.
[27] W. Parry-Smith et al., “Postpartum haemorrhage and risk of long-term hypertension and cardiovascular disease: An English population-based longitudinal study using linked primary and secondary care databases,” BMJ Open, vol. 11, no. 5, May 2021, doi: 10.1136/BMJOPEN-2020-041566.
[28] H. K. Bhachu et al., “Impact of Using Risk-Based Stratification on Referral of Patients With Chronic Kidney Disease From Primary Care to Specialist Care in the United Kingdom.,” Kidney Int. reports, vol. 6, no. 8, pp. 2189–2199, Aug. 2021, doi: 10.1016/j.ekir.2021.05.031.
[29] J. S. Chandan et al., “The association between exposure to domestic abuse in women and the development of syndromes indicating central nervous system sensitization: A retrospective cohort study using UK primary care records,” Eur. J. Pain (United Kingdom), vol. 25, no. 6, pp. 1283–1291, Jul. 2021, doi: 10.1002/ejp.1750.
[30] T. E. Gooden et al., “Incidence of cardiometabolic diseases in people living with and without HIV in the UK: a population-based matched cohort study.,” J. Infect. Dis., Aug. 2021, doi: 10.1093/infdis/jiab420.
[31] D. Keerthy et al., “Associations between primary care recorded cannabis use and mental ill health in the UK: a population-based retrospective cohort study using UK primary care data.,” Psychol. Med., pp. 1–10, Oct. 2021, doi: 10.1017/S003329172100386X.
[32] D. T. Zemedikun et al., “Burden of chronic diseases associated with periodontal diseases: A retrospective cohort study using UK primary care data,” BMJ Open, vol. 11, no. 12, Dec. 2021, doi: 10.1136/bmjopen-2020-048296.
[33] K. Okoth, J. Wang, D. Zemedikun, G. N. Thomas, K. Nirantharakumar, and N. J. Adderley, “Risk of cardiovascular outcomes among women with endometriosis in the United Kingdom: a retrospective matched cohort study,” BJOG An Int. J. Obstet. Gynaecol., vol. 128, no. 10, pp. 1598–1609, Sep. 2021, doi: 10.1111/1471-0528.16692.
[34] B. Kumarendran et al., “Polycystic ovary syndrome, combined oral contraceptives, and the risk of dysglycemia: A population-based cohort study with a nested pharmacoepidemiological case-control study,” Diabetes Care, vol. 44, no. 12, pp. 2758–2766, Dec. 2021, doi: 10.2337/dc21-0437.
[35] A. Vitalis et al., “The Impact of Atrial Fibrillation on Outcomes of Peripheral Arterial Disease: Analysis of Routinely Collected Primary Care Data.,” Am. J. Med., Nov. 2021, doi: 10.1016/j.amjmed.2021.10.021.
[36] J. S. Chandan et al., “The risk of COVID-19 in survivors of domestic violence and abuse,” BMC Med., vol. 19, no. 1, Dec. 2021, doi: 10.1186/s12916-021-02119-w.
[37] S. Haider et al., “Disease burden of diabetes, diabetic retinopathy and their future projections in the UK: Cross-sectional analyses of a primary care database,” BMJ Open, vol. 11, no. 7, Jul. 2021, doi: 10.1136/bmjopen-2021-050058.
[38] J. S. Chandan et al., “Female survivors of intimate partner violence and risk of depression, anxiety and serious mental illness,” Br. J. Psychiatry, vol. 217, no. 4, pp. 562–567, Oct. 2020, doi: 10.1192/BJP.2019.124.
[39] J. S. Chandan, K. Okoth, K. M. Gokhale, S. Bandyopadhyay, J. Taylor, and K. Nirantharakumar, “Increased cardiometabolic and mortality risk following childhood maltreatment in the United Kingdom,” J. Am. Heart Assoc., vol. 9, no. 10, May 2020, doi: 10.1161/JAHA.119.015855.
[40] F. Crowe et al., “Comorbidity phenotypes and risk of mortality in patients with ischaemic heart disease in the UK,” Heart, 2020, doi: 10.1136/HEARTJNL-2019-316091.
[41] T. Thomas et al., “Epidemiology, morbidity and mortality in Behçet’s disease: A cohort study using the Health Improvement Network (THIN),” Rheumatol. (United Kingdom), vol. 59, no. 10, pp. 2785–2795, Oct. 2020, doi: 10.1093/RHEUMATOLOGY/KEAA010.
[42] A. S. Tresoldi et al., “Increased Infection Risk in Addison’s Disease and Congenital Adrenal Hyperplasia,” J. Clin. Endocrinol. Metab., vol. 105, no. 2, Jan. 2020, doi: 10.1210/CLINEM/DGZ006.
[43] N. J. Adderley et al., “Obstructive sleep apnea, a risk factor for cardiovascular and microvascular disease in patients with type 2 diabetes: Findings from a population-based cohort study,” Diabetes Care, vol. 43, no. 8, pp. 1868–1877, Aug. 2020, doi: 10.2337/DC19-2116.
[44] P. Singh et al., “Impact of bariatric surgery on cardiovascular outcomes and mortality: a population-based cohort study,” Br. J. Surg., vol. 107, no. 4, pp. 432–442, Mar. 2020, doi: 10.1002/BJS.11433.
[45] A. Vusirikala et al., “Impact of obesity and metabolic health status in the development of non-alcoholic fatty liver disease (NAFLD): A United Kingdom population-based cohort study using the health improvement network (THIN),” BMC Endocr. Disord., vol. 20, no. 1, Jun. 2020, doi: 10.1186/S12902-020-00582-9.
[46] T. Braithwaite et al., “Trends in Optic Neuritis Incidence and Prevalence in the UK and Association with Systemic and Neurologic Disease,” JAMA Neurol., vol. 77, no. 12, pp. 1514–1523, Dec. 2020, doi: 10.1001/JAMANEUROL.2020.3502.
[47] J. S. Chandan, T. Thomas, C. Bradbury-Jones, J. Taylor, S. Bandyopadhyay, and K. Nirantharakumar, “Risk of Cardiometabolic Disease and All-Cause Mortality in Female Survivors of Domestic Abuse,” J. Am. Heart Assoc., vol. 9, no. 4, Feb. 2020, doi: 10.1161/JAHA.119.014580.
[48] D. King et al., “Changing patterns in the epidemiology and outcomes of inflammatory bowel disease in the United Kingdom: 2000-2018,” Aliment. Pharmacol. Ther., vol. 51, no. 10, pp. 922–934, May 2020, doi: 10.1111/APT.15701.
[49] J. S. Chandan, K. M. Gokhale, C. Bradbury-Jones, K. Nirantharakumar, S. Bandyopadhyay, and J. Taylor, “Exploration of trends in the incidence and prevalence of childhood maltreatment and domestic abuse recording in UK primary care: a retrospective cohort study using ‘the health improvement network’ database,” BMJ Open, vol. 10, no. 6, p. e036949, Jun. 2020, doi: 10.1136/BMJOPEN-2020-036949.
[50] J. S. Chandan et al., “The association between exposure to childhood maltreatment and the subsequent development of functional somatic and visceral pain syndromes,” EClinicalMedicine, vol. 23, Jun. 2020, doi: 10.1016/J.ECLINM.2020.100392.
[51] N. J. Adderley et al., “Association between Idiopathic Intracranial Hypertension and Risk of Cardiovascular Diseases in Women in the United Kingdom,” JAMA Neurol., vol. 76, no. 9, pp. 1088–1098, Sep. 2019, doi: 10.1001/JAMANEUROL.2019.1812.
[52] T. Taverner et al., “Circulating folate concentrations and risk of peripheral neuropathy and mortality: A retrospective cohort study in the U.K,” Nutrients, vol. 11, no. 10, Oct. 2019, doi: 10.3390/NU11102443.
[53] R. Thayakaran et al., “Impact of glycaemic control on fracture risk in 5368 people with newly diagnosed Type 1 diabetes: a time-dependent analysis,” Diabet. Med., vol. 36, no. 8, pp. 1013–1019, Aug. 2019, doi: 10.1111/DME.13945.
[54] K. A. Toulis, D. Viola, G. Gkoutos, D. Keerthy, K. Boelaert, and K. Nirantharakumar, “Risk of incident circulatory disease in patients treated for differentiated thyroid carcinoma with no history of cardiovascular disease,” Clin. Endocrinol. (Oxf)., vol. 91, no. 2, pp. 323–330, Aug. 2019, doi: 10.1111/CEN.13990.
[55] T. Thomas et al., “The Risk of Inflammatory Bowel Disease in Subjects Presenting with Perianal Abscess: Findings from the THIN Database,” J. Crohn’s Colitis, vol. 13, no. 5, pp. 600–606, Apr. 2019, doi: 10.1093/ECCO-JCC/JJY210.
[56] F. L. Crowe et al., “Non-linear associations of 25-hydroxyvitamin D concentrations with risk of cardiovascular disease and all-cause mortality: Results from The Health Improvement Network (THIN) database,” J. Steroid Biochem. Mol. Biol., vol. 195, Dec. 2019, doi: 10.1016/J.JSBMB.2019.105480.
[57] M. W. O’Reilly et al., “Serum testosterone, sex hormone-binding globulin and sex-specific risk of incident type 2 diabetes in a retrospective primary care cohort,” Clin. Endocrinol. (Oxf)., vol. 90, no. 1, pp. 145–154, Jan. 2019, doi: 10.1111/CEN.13862.
[58] A. Tracy et al., “Cardiovascular, thromboembolic and renal outcomes in IgA vasculitis (Henoch-Schönlein purpura): A retrospective cohort study using routinely collected primary care data,” Ann. Rheum. Dis., vol. 78, no. 2, pp. 261–269, Feb. 2019, doi: 10.1136/ANNRHEUMDIS-2018-214142.
[59] A. Ntouva et al., “Hypoglycaemia is associated with increased risk of fractures in patients with type 2 diabetes mellitus: A cohort study,” Eur. J. Endocrinol., vol. 180, no. 1, pp. 51–58, Jan. 2019, doi: 10.1530/EJE-18-0458.
[60] A. Lavrentaki et al., “Increased risk of non-alcoholic fatty liver disease in women with gestational diabetes mellitus: A population-based cohort study, systematic review and meta-analysis,” J. Diabetes Complications, vol. 33, no. 10, Oct. 2019, doi: 10.1016/J.JDIACOMP.2019.06.006.
[61] A. Mittal, M. E. Hassan, J. S. Chandan, B. H. Willis, K. Nirantharakumar, and K. Subramonian, “Cancer as a risk factor for urinary tract calculi: a retrospective cohort study using ‘The Health Improvement Network’: Cancer and urinary tract calculi,” Urolithiasis, vol. 47, no. 6, pp. 541–547, Dec. 2019, doi: 10.1007/S00240-019-01127-Z.
[62] R. Thayakaran et al., “Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: Longitudinal study,” BMJ, vol. 366, 2019, doi: 10.1136/BMJ.L4892.
[63] B. Kumarendran et al., “Increased risk of obstructive sleep apnoea in women with polycystic ovary syndrome: A population-based cohort study,” Eur. J. Endocrinol., vol. 180, no. 4, pp. 265–272, Apr. 2019, doi: 10.1530/EJE-18-0693.
[64] H. K. Bhachu, P. Cockwell, A. Subramanian, K. Nirantharakumar, D. Kyte, and M. Calvert, “Cross-sectional observation study to investigate the impact of risk-based stratification on care pathways for patients with chronic kidney disease: Protocol paper,” BMJ Open, vol. 9, no. 6, Jun. 2019, doi: 10.1136/BMJOPEN-2018-027315.
[65] J. S. Chandan, T. Thomas, C. Bradbury-Jones, J. Taylor, S. Bandyopadhyay, and K. Nirantharakumar, “Intimate partner violence and temporomandibular joint disorder,” J. Dent., vol. 82, pp. 98–100, Mar. 2019, doi: 10.1016/J.JDENT.2019.01.008.
[66] P. R. Harvey, T. Thomas, J. S. Chandan, N. Bhala, K. Nirantharakumar, and N. J. Trudgill, “Outcomes following feeding gastrostomy (FG) insertion in patients with learning disability: A retrospective cohort study using the health improvement network (THIN) database,” BMJ Open, vol. 9, no. 6, Jun. 2019, doi: 10.1136/BMJOPEN-2018-026714.
[67] J. S. Chandan, T. Thomas, K. M. Gokhale, S. Bandyopadhyay, J. Taylor, and K. Nirantharakumar, “The burden of mental ill health associated with childhood maltreatment in the UK, using The Health Improvement Network database: a population-based retrospective cohort study,” The Lancet Psychiatry, vol. 6, no. 11, pp. 926–934, Nov. 2019, doi: 10.1016/S2215-0366(19)30369-4.
[68] A. Subramanian et al., “Risk of incident obstructive sleep apnea among patients with type 2 diabetes,” Diabetes Care, vol. 42, no. 5, pp. 954–963, May 2019, doi: 10.2337/DC18-2004.
[69] M. T. Krishna, A. Subramanian, N. J. Adderley, D. T. Zemedikun, G. V. Gkoutos, and K. Nirantharakumar, “Allergic diseases and long-term risk of autoimmune disorders: Longitudinal cohort study and cluster analysis,” Eur. Respir. J., vol. 54, no. 5, Nov. 2019, doi: 10.1183/13993003.00476-2019.
[70] N. Adderley, K. Nirantharakumar, and T. Marshall, “Temporal variation in the diagnosis of resolved atrial fibrillation and the influence of performance targets on clinical coding: Cohort study,” BMJ Open, vol. 9, no. 11, Nov. 2019, doi: 10.1136/BMJOPEN-2019-030454.
[71] N. J. Adderley, K. Nirantharakumar, and T. Marshall, “Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: Retrospective cohort studies,” BMJ, vol. 361, 2018, doi: 10.1136/BMJ.K1717.
[72] P. R. Harvey et al., “Incidence, morbidity and mortality of patients with achalasia in England: Findings from a study of nationwide hospital and primary care data,” Gut, Jun. 2018, doi: 10.1136/GUTJNL-2018-316089.
[73] B. Daly et al., “Increased risk of ischemic heart disease, hypertension, and type 2 diabetes in women with previous gestational diabetes mellitus, a target group in general practice for preventive interventions: A population-based cohort study,” PLoS Med., vol. 15, no. 1, Jan. 2018, doi: 10.1371/JOURNAL.PMED.1002488.
[74] K. A. Toulis et al., “Initiation of dapagliflozin and treatment-emergent fractures,” Diabetes, Obes. Metab., vol. 20, no. 4, pp. 1070–1074, Apr. 2018, doi: 10.1111/DOM.13176.
[75] J. S. Chandan et al., “The association between idiopathic thrombocytopenic purpura and cardiovascular disease: a retrospective cohort study,” J. Thromb. Haemost., vol. 16, no. 3, pp. 474–480, Mar. 2018, doi: 10.1111/JTH.13940.
[76] K. Nirantharakumar, N. Mohammed, K. A. Toulis, G. N. Thomas, and P. Narendran, “Clinically meaningful and lasting HbA1c improvement rarely occurs after 5 years of type 1 diabetes: an argument for early, targeted and aggressive intervention following diagnosis,” Diabetologia, vol. 61, no. 5, pp. 1064–1070, May 2018, doi: 10.1007/S00125-018-4574-6.
[77] K. A. Toulis et al., “Males with prolactinoma are at increased risk of incident cardiovascular disease,” Clin. Endocrinol. (Oxf)., vol. 88, no. 1, pp. 71–76, Jan. 2018, doi: 10.1111/CEN.13498.
[78] B. Kumarendran et al., “Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database,” PLoS Med., vol. 15, no. 3, Mar. 2018, doi: 10.1371/JOURNAL.PMED.1002542.
[79] G. E. Dafoulas et al., “Type 1 diabetes mellitus and risk of incident epilepsy: a population-based, open-cohort study,” Diabetologia, vol. 60, no. 2, pp. 258–261, Feb. 2017, doi: 10.1007/S00125-016-4142-X.
[80] R. Caleyachetty et al., “Metabolically Healthy Obese and Incident Cardiovascular Disease Events Among 3.5 Million Men and Women,” J. Am. Coll. Cardiol., vol. 70, no. 12, pp. 1429–1437, Sep. 2017, doi: 10.1016/J.JACC.2017.07.763.
[81] K. A. Toulis et al., “All-cause mortality in patients with diabetes under glucagon-like peptide-1 agonists: A population-based, open cohort study,” Diabetes Metab., vol. 43, no. 3, pp. 211–216, Jun. 2017, doi: 10.1016/J.DIABET.2017.02.003.
[82] K. A. Toulis et al., “All-cause mortality in patients with diabetes under treatment with dapagliflozin: A population-based, open-cohort study in the health improvement network database,” J. Clin. Endocrinol. Metab., vol. 102, no. 5, pp. 1719–1725, May 2017, doi: 10.1210/JC.2016-3446.